197 related articles for article (PubMed ID: 35380160)
1. Inhibition of activin A receptor signalling attenuates age-related pathological cardiac remodelling.
Clavere NG; Alqallaf A; Rostron KA; Parnell A; Mitchell R; Patel K; Boateng SY
Dis Model Mech; 2022 May; 15(5):. PubMed ID: 35380160
[TBL] [Abstract][Full Text] [Related]
2. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
3. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
4. A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.
Frentzou GA; Drinkhill MJ; Turner NA; Ball SG; Ainscough JF
Dis Model Mech; 2015 Aug; 8(8):783-94. PubMed ID: 26092119
[TBL] [Abstract][Full Text] [Related]
5. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
[TBL] [Abstract][Full Text] [Related]
6. Regulator of G protein signalling 14 attenuates cardiac remodelling through the MEK-ERK1/2 signalling pathway.
Li Y; Tang XH; Li XH; Dai HJ; Miao RJ; Cai JJ; Huang ZJ; Chen AF; Xing XW; Lu Y; Yuan H
Basic Res Cardiol; 2016 Jul; 111(4):47. PubMed ID: 27298141
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model.
Alqallaf A; Engelbeen S; Palo A; Cutrupi F; Tanganyika-de Winter C; Plomp J; Vaiyapuri S; Aartsma-Rus A; Patel K; van Putten M
Neuromuscul Disord; 2022 May; 32(5):419-435. PubMed ID: 35465969
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.
Myllärniemi M; Tikkanen J; Hulmi JJ; Pasternack A; Sutinen E; Rönty M; Leppäranta O; Ma H; Ritvos O; Koli K
BMC Pulm Med; 2014 Nov; 14():170. PubMed ID: 25361680
[TBL] [Abstract][Full Text] [Related]
9. Regulation and actions of activin A and follistatin in myocardial ischaemia-reperfusion injury.
Chen Y; Rothnie C; Spring D; Verrier E; Venardos K; Kaye D; Phillips DJ; Hedger MP; Smith JA
Cytokine; 2014 Oct; 69(2):255-62. PubMed ID: 25052838
[TBL] [Abstract][Full Text] [Related]
10. The POU4F2/Brn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart.
Mele L; Maskell LJ; Stuckey DJ; Clark JE; Heads RJ; Budhram-Mahadeo VS
Cell Death Dis; 2019 Aug; 10(8):621. PubMed ID: 31413277
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction.
Ainscough JF; Drinkhill MJ; Sedo A; Turner NA; Brooke DA; Balmforth AJ; Ball SG
Cardiovasc Res; 2009 Feb; 81(3):592-600. PubMed ID: 18703536
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen Receptor β Activation Protects Against Myocardial Infarction via Notch1 Signalling.
Du M; Shan J; Feng A; Schmull S; Gu J; Xue S
Cardiovasc Drugs Ther; 2020 Apr; 34(2):165-178. PubMed ID: 32157565
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction.
Xia Y; Zhang F; Zhao S; Li Y; Chen X; Gao E; Xu X; Xiong Z; Zhang X; Zhang J; Zhao H; Wang W; Wang H; Guo Y; Liu Y; Li C; Wang S; Zhang L; Yan W; Tao L
Cardiovasc Res; 2018 Aug; 114(10):1335-1349. PubMed ID: 29668847
[TBL] [Abstract][Full Text] [Related]
14. Novel Protective Role of Myeloid Differentiation 1 in Pathological Cardiac Remodelling.
Xiong X; Liu Y; Mei Y; Peng J; Wang Z; Kong B; Zhong P; Xiong L; Quan D; Li Q; Wang G; Huang H
Sci Rep; 2017 Feb; 7():41857. PubMed ID: 28165494
[TBL] [Abstract][Full Text] [Related]
15. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.
He Z; Zhang X; Chen C; Wen Z; Hoopes SL; Zeldin DC; Wang DW
Cardiovasc Res; 2015 Mar; 105(3):304-17. PubMed ID: 25618409
[TBL] [Abstract][Full Text] [Related]
16. Activin type II receptor signaling in cardiac aging and heart failure.
Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
[TBL] [Abstract][Full Text] [Related]
17. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
[TBL] [Abstract][Full Text] [Related]
18. Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice.
Liu Y; Jiang XL; Liu Y; Jiang DS; Zhang Y; Zhang R; Chen Y; Yang Q; Zhang XD; Fan GC; Li H
Cardiovasc Res; 2014 Jan; 101(1):87-96. PubMed ID: 24285748
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
Rüdebusch J; Benkner A; Nath N; Fleuch L; Kaderali L; Grube K; Klingel K; Eckstein G; Meitinger T; Fielitz J; Felix SB
Br J Pharmacol; 2022 Jun; 179(11):2430-2442. PubMed ID: 33247945
[TBL] [Abstract][Full Text] [Related]
20. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy.
Viereck J; Bührke A; Foinquinos A; Chatterjee S; Kleeberger JA; Xiao K; Janssen-Peters H; Batkai S; Ramanujam D; Kraft T; Cebotari S; Gueler F; Beyer AM; Schmitz J; Bräsen JH; Schmitto JD; Gyöngyösi M; Löser A; Hirt MN; Eschenhagen T; Engelhardt S; Bär C; Thum T
Eur Heart J; 2020 Sep; 41(36):3462-3474. PubMed ID: 32657324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
